Biogen

In News

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion - WSJ

WSJ - Mar 31, 2026

Cantor Fitzgerald cuts Apellis stock rating on Biogen acquisition - investing.com

investing.com - Apr 01, 2026

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology - Biogen

Biogen - Mar 31, 2026

Biogen to acquire immunology biotech Apellis for $5.6 billion - statnews.com

statnews.com - Mar 31, 2026

Biogen to Buy Apellis for $5.6 Billion to Boost Kidney Franchise - bloomberg.com

bloomberg.com - Mar 31, 2026

Why Biogen Stock Sank While the Market Soared on Thursday - The Motley Fool

The Motley Fool - Apr 01, 2026

Why Biogen Stock Sank While the Market Soared on Thursday - Yahoo Finance

Yahoo Finance - Apr 01, 2026

Biogen Reports Positive Phase 2 Results for Litifilimab for Treatment of Cutaneous Lupus Erythematosus - Lupus Foundation of America

Lupus Foundation of America - Mar 31, 2026

Lilly Acquires Centessa for Up to $7.8B; Biogen Buys Apellis for Up to $6.1B - Genetic Engineering and Biotechnology News

Genetic Engineering and Biotechnology News - Mar 31, 2026

Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza - Zacks Investment Research

Zacks Investment Research - Mar 31, 2026

Apellis Stock More Than Doubles on Biogen News. Here’s What to Know. - Barron's

Barron's - Mar 31, 2026

Biogen scoops up Apellis for $5.6B, adding eye and kidney drugs - FirstWord Pharma

FirstWord Pharma - Mar 31, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment